A phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis (The LASER-TBM Trial).
Angharad G DavisSean WassermanCari StekMpumi MaxebengulaC Jason LiangStephani StegmannSonya KoekemoerAmanda JacksonYakub KadernaniMarise BremerRemy DaroowalaSaalikha AzizRene GoliathLouise Lai SaiThandi SihoyiyaPaolo DentiRachel Pj LaiThomas CredeJonathan NaudePatryk SzymanskiYakoob VallieIsmail Abbas BanderkerMuhammed S MoosaPeter RaubenheimerSally CandyCurtis OffiahGerda WahlIsak VorsterGary MaartensJohn BlackGraeme MeintjesRobert J WilkinsonPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
High-dose rifampicin and adjunctive linezolid can safely be added to SOC in HIV-associated TBM. Larger studies are required to evaluate whether potential toxicity associated with these interventions, particularly high-dose aspirin, is outweighed by mortality or morbidity benefit.
Keyphrases
- high dose
- low dose
- antiretroviral therapy
- hiv positive
- hiv infected
- hiv testing
- cardiovascular events
- human immunodeficiency virus
- phase iii
- stem cell transplantation
- mycobacterium tuberculosis
- study protocol
- hepatitis c virus
- hiv aids
- phase ii
- open label
- men who have sex with men
- clinical trial
- methicillin resistant staphylococcus aureus
- antiplatelet therapy
- pulmonary tuberculosis
- coronary artery disease
- risk factors
- type diabetes
- cardiovascular disease
- acute coronary syndrome
- double blind
- placebo controlled
- human health
- anti inflammatory drugs
- mass spectrometry
- high speed
- climate change
- oxide nanoparticles